Get started
Author

Rob Purdie

ORCID: 0009-0009-0787-6578
Observed ORCID: 0009-0009-0787-6578
OpenAlex ID: A5091152146
FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
2021 · Elizabeth O’Shaughnessy, Yuliya Yasinskaya, et al. · Clinical Infectious Diseases · 12
Antimicrobial resistance survivors: calling the world to action
2024 · Nour Shamas, John Kariuki, et al. · The Lancet · 8
Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit
2024 · Rob Purdie, Lisa A Tushla, et al. · Open Forum Infectious Diseases · 6
Development of a novel patient-reported outcome measure for disseminated coccidioidomycosis (valley fever)
2024 · Emma Harvey, Jennifer Clegg, et al. · Journal of Antimicrobial Chemotherapy · 3
PDF
The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?
2025 · Kavitha Thiagarajan, Shikha Mishra, et al. · Journal of Fungi · 2
PDF
Advancing Patient Advocacy in Mycology: Cultivating Collaboration in Education, Research, and Policy
2025 · Rob Purdie, Rasha Kuran, et al. · Mycopathologia
PDF
2516. Development of a de novo Patient-Reported Outcome (PRO) Measure to Assess the Impacts of Disseminated Coccidioidomycosis [Valley Fever] on Patients Living with the Condition
2023 · Emma L Harvey, Mark Bresnik, et al. · Open Forum Infectious Diseases
PDF
Works count: 7
Citation count: 31
H-index: 3
I10-index: 1
Year
Topic
Type